Pacira | PCRX - Operating Profit


Pacira reported $9.96M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Astellas Pharma JPY 185.36B 136.79B Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
J&J USD 7.48B 860M Jun/2026
Ligand Pharmaceuticals USD 56.62M 3.7M Jun/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Novo Nordisk DKK 33.76B 25.86B Jun/2026
Omeros USD -35.41M 23.75M Sep/2024
Pacira USD 9.96M 5.33M Jun/2026
Perrigo USD 23.5M 10.1M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
Teva Pharmaceutical Industries USD 235M 523M Jun/2026
Xeris Pharmaceuticals USD 7.92M 8.86M Mar/2026
Zoetis USD 1.12B 256M Jun/2026